| Qionghai | Turkey | Austria | |
| CAR T-cell therapy | ≈ $319,000 | from $200,000 | ≈ $280,000 |
| CAR-T for Pediatric ALL | ≈ $130,000 | ≈ $140,000 | ≈ $290,000 |
| CAR-T for Multiple Myeloma | from $147,500 | ≈ $140,000 | ≈ $330,000 |
| CAR-T for DLBCL | ≈ $165,000 | ≈ $140,000 | ≈ $290,000 |
No hidden fees – just official clinic prices. Pay at the clinic for CAR T-cell therapy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in CAR T-cell therapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your CAR T-cell therapy journey.
Day 1
Day 2 - Day 3
Day 4
Day 5 - Day 12
Day 13
Day 14 - Day 20
Week 3 - Week 4
Week 5 onwards
Please note that each case is individual. This timeline may vary based on your personal health condition and the specifics of your treatment plan.
Dr. Luan Tianyan, MD, is Head of Oncology. He was recruited to Hainan Province as a high-level talent. He is a visiting scholar at the Dana-Farber Cancer Institute (USA). He is also Director of the Clinical Research Office at Bozheng Hengda International Hospital. He serves on the standing committees of the Clinical Research Management Committee (Southern Oncology Clinical Research Association), the Immunotherapy Committee (Hainan Provincial Anti-Cancer Association), and the Hainan Province Drug Research Committee.
He has more than 20 years of oncology practice. He provides individualized, comprehensive care for gastrointestinal tumors, lung cancer, and breast cancer. He focuses on pain management, palliative care, and psychological support in advanced cancer. He also works on the clinical use and study of tumor immunotherapy, including personalized mRNA vaccines and CAR-T therapy. He develops and applies proprietary drugs and related technologies.
Dr. Chen Binglai is a biological immunology expert (MD). He holds a PhD in Medicine from Central South University, with a focus on genetics and integrated TCM and Western medicine. He completed postdoctoral training at New York University and the University of Bologna. He is a visiting professor at Zhongshan Hospital, Fudan University.
He is affiliated with the Shanghai Pujiang Talent Program and the Yangpu District 3310 Talent Program. He leads the innovation project “Cancer Treatment Based on Cell Culture Technology,” supported by the Pujiang Program.
He has years of oncology practice and extensive experience in treating malignant tumors. His work focuses on the clinical use and research of CAR-T, NK cell, and stem cell therapies. He uses the Lecheng pilot program to advance clinical translation in China and to offer personalized treatment plans.
Written by Anna Leonova